A follow-up letter to FDA Commissioner, Andrew vonEschenbach RE: Thomas Laughren, FDA’s ‘s Director of Psychiatry Products who has been actively promoting psychotropic drugs–even penning his name to ghostwritten industry-sponsored articles and consensus panels. Continue reading →
The re-prioritization of rapid approvals occurred at the expense of drug safety standards, Continue reading →
The question is: will Eli Lilly succeed, once again, to divert public attention from the revelations contained in its internal documents about the company's illegal marketing practices and its failure to warn about lethal risks posed by its product?
Dr. Peter Breggin’s sealed expert medical report in a Paxil liability case is now in the public domain.
Continue reading →